Adefovir Dipivoxil Api
₹2,250.00
Applications
Adefovir dipivoxil is a nucleoside analogue used for chronic hepatitis B infection, including against lamivudine-resistant strains. It is administered as the oral prodrug (plasma t½ 8 h, intracellular t½ of active metabolite 17 h).
Description
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.
Preparation
The synthesis of adefovir dipivoxil is completed by addition of the chloromethyl pivalate to a solution of the corresponding phosphonic acid in N-methylpyrrolidone (NMP), using triethylamine as base. Figure 2. Synthetic scheme of crystalline adefovir dipivoxil.
Chemical Properties
Adefovir dipivoxil API is a white to off-white crystalline powder with low solubility in water, recognized for its antiviral properties in treating chronic hepatitis B by inhibiting viral DNA polymerase.
Definition
Adefovir dipivoxil API is an organic compound used in the treatment of chronic hepatitis B, functioning as a nucleotide analogue inhibiting viral DNA replication.
Description
| Product Name | Adefovir Dipivoxil Api |
| Country of Origin | Made in India |
| Usage | Pharma |
| CAS ID | 142340-99-6 |
| Formula | C8H12N5O4P |
| Molar Mass | 273.186 g/mol |
| Protein Binding | 4% |
| Elimination half-life | 7.5 hrs |
| Molecular Formula | C20H32N5O8P |
| Molecular Weight | 501.47 |
| Melting point | 98-102°C |
| Boiling point | 641.0±65.0 °C(Predicted) |
| Density | 1.35±0.1 g/cm3(Predicted) |
| storage temp | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| solubility | ethanol: soluble50mg/mL |
| pka | 4.16±0.10(Predicted) |
| form | solid |
| color | White to Off-White |
| Packaging Size | As Per Requirement |
Our Export Location as a Adefovir Dipivoxil Api Manufacturer, Supplier, Exporter, Stockist from India.
 Afghanistan
|
 Bosnia and Herzegovina
|
 Cote d’Ivoire
|
 Schaumburg-Lippe*
|
 India
|
Albania
Algeria
Andorra
Angola
Antigua and Barbuda
Argentina
Armenia
Australia
Austria
Austrian Empire
Azerbaijan
Baden
Bahamas
Bahrain
Bangladesh
Barbados
Bavaria
Belarus
Belgium
Belize
Benin (Dahomey)
Bolivia
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mecklenburg-Schwerin
Mecklenburg-Strelitz
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Botswana
Brazil
Brunei
Brunswick and Lüneburg
Bulgaria
Burkina Faso 
Burma
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands
Central African Republic
Central American Federation
Chad
Chile
China
Colombia
Comoros
Congo Free State
Costa Rica
Morocco
Mozambique
Namibia
Nassau
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
North German Confederation
North German Union
North Macedonia
Norway
Oldenburg
Oman
Orange Free State
Pakistan
Palau
Panama
Papal States
Croatia
Cuba
Cyprus
Czechia
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Duchy of Parma
East Germany
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Federal Government of Germany
Fiji
Papua New Guinea
Paraguay
Peru
Philippines
Piedmont-Sardinia
Poland
Portugal
Qatar
Republic of Genoa*
Republic of Korea (South Korea)
Republic of the Congo
Romania
Russia
Rwanda
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Grand Duchy of Tuscany
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Hanover
Hanseatic Republics
Hawaii
Hesse
Holy See
Honduras
Hungary
Iceland
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Texas
Thailand
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kingdom of Serbia/Yugoslavia
Kiribati
Korea
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Lew Chew (Loochoo)
Timor-Leste
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Two Sicilies*
Uganda
Ukraine
Union of Soviet Socialist Republics*
United Arab Emirates
United Kingdom
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Württemberg*
Yemen
Zambia
ZimbabweRelated products
-
- Sale!
- API and intermediate
Etoricoxib
- ₹10,000.00
-
- Sale!
- API and intermediate
Fexofenadine Hydrochloride
- ₹5,400.00
-
- Sale!
- API and intermediate
Eptifibatide
- ₹9,450.00
Reviews
There are no reviews yet.